About ERN LUNG
Expertise
patients
clinicians
ERN-LUNG Academy

The ERN-LUNG Academy is a curriculum for medical staff at any stage of their career, who wishes to get a proof of knowledge on rare respiratory diseases. It consists of Webinars and eCases, but also includes on-site training in ERN-LUNG Centers. We call for applications from participants of EU-member States from September to November each year. Classes start in January. If you wish to apply for next yearโ€™s class, please send a letter of motivation to info@ern-lung.eu

ERN-LUNG Online advance system

The EXpert Advisory BOard (EXABO) is a pan-European internet platform, which has been developed in the context of ERN-LUNG in liaison with the Medical Informatics Group of University Hospital Frankfurt, to answer questions on all aspects of rare respiratory diseases. The platform is primarily aimed at patients and care team members but is openly accessible by anyone who wants to ask a related question.

NETWORK
News

ERS Alpha-1 Antitrypsin Conference 2026

DATE:ย  23 Oct 2026 – 24 Oct 2026
TIME: 0:00

23-24 October, 2026 | Barcelona, Spain

Organizing committee:ย Dr. Miriam Barrecheguren Fernandez, Prof. Dr Didier Cataldo, Dr Christian Clarenbach, Prof. Dr Marc Miravitlles, Dr Alice Turner, Mrs Marion Wilkens

The first ERS Alpha-1 Antitrypsin Conference – October 2026

The first ERS Alpha-1 Antitrypsin Conference 2026 will take place in Barcelona, Spain, on 23-24 October 2026.

 

This two-day meeting will gather clinicians, scientists, laboratory experts and patient representatives to review current knowledge, present new findings and discuss future directions in AATD research and care.

Through state-of-the-art lectures, interactive discussions and abstract presentations, the programme will explore:

  • Relevance of circulating polymers of AAT
  • Pathogenicity of rare AAT variants
  • AATD-associated liver disease for pulmonologists
  • EARCO – new research advances
  • Strategies for diagnosis and follow-up of patients with AATD
  • Clinical phenotypes and heterogeneity in Alpha-1
  • New modalities of treatment for AATD